Omeros Receives Negative EU Opinion on Narsoplimab
Omeros said the EMA’s CHMP issued a negative opinion on its EU marketing application for narsoplimab in TA-TMA after re-examination. The drug is FDA-approved in the U.S. as YARTEMLEA.
Omeros said the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion, following re-examination, on the company’s EU marketing application for narsoplimab in TA-TMA. The drug is approved by the FDA in the U.S. under the name YARTEMLEA.